Growth-hormone-releasing peptide 6 (GHRP6) prevents oxidant cytotoxicity and reduces myocardial necrosis in a model of acute myocardial infarction
Jorge Berlanga(Centro de Ingeniería Genética y Biotecnología), Nelson Santiago Vispo(Centro de Ingeniería Genética y Biotecnología), Ernesto López‐Mola(Centro de Ingeniería Genética y Biotecnología), José Suárez Alba(Centro de Ingeniería Genética y Biotecnología), Alina Seralena(Centro de Ingeniería Genética y Biotecnología), Gerardo Guillén(Hunan City University), Heberto Dominguez, Danay Cibrián(Instituto de Salud Carlos III), Brumny Perez(Centro de Ingeniería Genética y Biotecnología), Pedro López‐Saura(United States Nuclear Regulatory Commission), Luis Guevara(Hermanos Ameijeiras Hospital), Alberto Domínguez Rodríguez(Hospital Universitario de Canarias), Diana García(Centro de Ingeniería Genética y Biotecnología)
Cited by 21
Related Papers
CD69: from activation marker to metabolic gatekeeper
|European Journal of Immunology|2017|935
Epidermal growth factor in clinical practice – a review of its biological actions, clinical indications and safety implications
|International Wound Journal|2009|167
A novel cancer vaccine composed of human-recombinant epidermal growth factor linked to a carrier protein: Report of a pilot clinical trial
|Annals of Oncology|1998|155
Glucose Toxic Effects on Granulation Tissue Productive Cells: The Diabetics’ Impaired Healing
|BioMed Research International|2012|153
Wound Chronicity, Impaired Immunity and Infection in Diabetic Patients
|MEDICC Review|2021|139